Impurity profiling strategy systematically identifies, quantifies, and characterises manufacturing-related and degradation impurities. Forced degradation studies generate representative impurity profiles. Chromatographic separation isolates pure impurity standards. Structure elucidation via mass spectrometry and NMR identifies molecules. Risk assessment prioritises high-concern impurities.
Regulatory submissions include comprehensive impurity profiles. Specification limits establish acceptable impurity levels. Stability monitoring detects emerging impurities requiring investigation. Manufacturing improvements reduce impurity formation. Post-approval monitoring ensures continued compliance.
General Biopharmaceutical Concepts
Impurity Profiling Strategy
Impurity profiling strategy identifies, characterises and controls impurities throughout pharmaceutical development to ensure product quality and patient safety.
Continue Exploring
Browse over 900 biopharmaceutical terms across biologics, ADCs, cell & gene therapy, CMC, clinical development and manufacturing.
Browse Glossary →